Welcome to our dedicated page for Hepion Pharmaceuticals news (Ticker: HEPA), a resource for investors and traders seeking the latest updates and insights on Hepion Pharmaceuticals stock.
Hepion Pharmaceuticals, Inc. (HEPA) generates news that reflects its transition from liver-focused drug development to diagnostic testing and its evolving capital markets profile. Company announcements describe Hepion as a clinical stage biopharmaceutical firm that had been developing rencofilstat, a cyclophilin inhibitor for non-alcoholic steatohepatitis (NASH), hepatocellular carcinoma (HCC) and other chronic liver diseases, and that is now concentrating on diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), helicobacter pylori (H. pylori) and HCC.
News items for HEPA commonly cover strategic shifts and partnerships, such as Hepion’s license agreement with New Day Diagnostics LLC to in-license diagnostic tests in these areas. Releases also discuss the status of its ASCEND-NASH Phase 2b clinical trial, including the decision to wind down and close the trial, and the subsequent sale of rencofilstat-related patent assets, knowhow and clinical data in exchange for a nominal amount and a contingent value right for stockholders.
Investors following HEPA will also find capital markets and listing updates in the news feed. Hepion has reported a reverse stock split intended to address Nasdaq’s minimum bid price requirement, a public offering of common stock and warrants, and later a delisting notification from Nasdaq citing continued listing standard deficiencies and concerns that the company was a public shell. Subsequent news confirms the suspension of trading on Nasdaq and the transition of HEPA shares to quotation on the OTCQB Venture Market.
The HEPA news stream further includes corporate transaction and governance developments, including the proposed but ultimately terminated merger with Pharma Two B Ltd., the effectiveness and later cancellation of a special stockholder meeting related to that transaction, and leadership changes such as the appointment of an interim Chief Executive Officer and the resignation of a chief financial officer and director. For readers tracking the company’s evolution toward precision diagnostics and its efforts to manage capital and strategic alternatives, the HEPA news page offers an organized view of these disclosures.
Hepion Pharmaceuticals (NASDAQ:HEPA) has announced the launch of AI-POWR™, a proprietary AI and machine learning platform aimed at improving drug development for non-alcoholic steatohepatitis (NASH). AI-POWR™ utilizes a multi-omics approach to enhance patient selection and optimize clinical trial outcomes for Hepion's lead drug candidate, CRV431, which is currently in a Phase 2a trial. The initiative is expected to reduce costs and development timelines while enhancing the likelihood of clinical success.
Hepion Pharmaceuticals (NASDAQ:HEPA) announced that CEO Dr. Robert Foster will present virtually at the H.C. Wainwright 4th Annual NASH Conference on October 5, 2020, at 4:00 p.m. E.T. The presentation will be accessible live and archived on the company’s website under the 'Events' section. Hepion focuses on developing therapies for liver diseases, particularly non-alcoholic steatohepatitis (NASH). Its lead candidate, CRV431, targets liver fibrosis and exhibits antiviral properties, showcasing potential in treating various liver diseases.
Hepion Pharmaceuticals (NASDAQ:HEPA) announced positive findings from a study by the National Institute of Allergy and Infectious Diseases (NIAID), showing that its drug candidate CRV431 exhibits significant antiviral activity against SARS-CoV-2. The study found CRV431 inhibited viral production with an IC90 of 1.5 μM, nearly five times more potent than a control compound. No significant cellular toxicity was observed. Hepion aims to advance CRV431 through further studies while maintaining focus on its current phase 2a program for NASH.
Hepion Pharmaceuticals announced the completion of CRV431 dosing in all subjects for its Phase 1b multiple ascending dose study. This study aimed to evaluate the safety, tolerability, and pharmacokinetics of CRV431, with doses ranging from 75 mg to 375 mg administered to healthy volunteers. The drug was well tolerated at all levels. Hepion is advancing to its Phase 2a AMBITION trial, expecting to complete the 75 mg dosing by the end of 2020. The study's outcomes are vital for further drug development targeting liver diseases like NASH.
Hepion Pharmaceuticals (NASDAQ:HEPA) announced it will present a poster on CRV431's antifibrotic activity at the Digital International Liver Congress™ 2020 from August 27-29. Dr. Joseph Kuo will discuss a preclinical study highlighting CRV431's ability to reduce hepatic fibrosis and weight gain in a NASH mouse model. The presentation is scheduled for August 28, 2020, under poster number FRI-239. Hepion aims to develop targeted therapies for liver diseases, with CRV431 showing promise in reducing fibrosis and hepatocellular carcinoma tumor burden.
Hepion Pharmaceuticals announced a study published in PLOS ONE demonstrating that its lead drug candidate, CRV431, effectively inhibits hepatitis C virus (HCV) infection in a humanized liver mouse model. The study showed that CRV431 administration resulted in complete suppression of HCV replication with no viral rebound observed five months post-treatment. The findings highlight CRV431's potential utility against various viral infections, including COVID-19. Hepion is advancing CRV431 through a Phase 2a clinical trial for NASH.
Hepion Pharmaceuticals announced that a peer-reviewed study published in PLOS ONE demonstrated that CRV431, its leading drug candidate, effectively inhibited hepatitis C virus (HCV) infection in a humanized liver mouse model with no observed viral rebound after five months. This study supports CRV431's antiviral potential and adds to existing data indicating its efficacy against multiple viral infections, including hepatitis B and HIV. The drug is currently in a Phase 2a clinical trial for treating liver disease due to NASH.